Diligence memo · auto-generated · as of July 2, 2026
Neotropix Inc
Neotropix Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Neotropix Inc operates in Pharmaceuticals, based in Chester Springs.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Neotropix Inc has raised $1.4M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.4M on 2009-04-30.
Most recent recorded round closed around 2009-04-30.
Valuation (modeled)modeled
Provath models Neotropix Inc at approximately $53M (range $1.1M–$418M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.66× the median modeled value of Seed Pharmaceuticals companies in 2007–2009 (25 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Last raise 17.2 yr ago; this sector typically re-raises about every 13 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 23% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 44% of those peers.
Closest niche peers: Sequoia Pharmaceuticals Inc, Spring Pharmaceuticals, LLC, Oceana Therapeutics, Inc., Supergen Inc, Archer Pharmaceuticals, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.